GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » Median PS Value

Astellas Pharma (Astellas Pharma) Median PS Value : $14.41 (As of Apr. 27, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Astellas Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $6.025. Astellas Pharma's 10-Year median PS Ratio is 2.3917. Therefore, the Median PS Value for today is $14.41.

As of today (2024-04-27), Astellas Pharma's share price is $9.55. Astellas Pharma's Median PS Value is $14.41. Therefore, Astellas Pharma's Price to Median PS Value for today is 0.66.

The historical rank and industry rank for Astellas Pharma's Median PS Value or its related term are showing as below:

ALPMY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.66   Med: 1   Max: 1.26
Current: 0.66

During the past 13 years, the highest Price to Median PS Value of Astellas Pharma was 1.26. The lowest was 0.66. And the median was 1.00.

ALPMY's Price-to-Median-PS-Value is ranked better than
61.4% of 500 companies
in the Drug Manufacturers industry
Industry Median: 0.8 vs ALPMY: 0.66

Astellas Pharma Median PS Value Historical Data

The historical data trend for Astellas Pharma's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Median PS Value Chart

Astellas Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.41 15.28 15.06 14.45 16.15

Astellas Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.67 16.15 14.85 14.54 15.51

Competitive Comparison of Astellas Pharma's Median PS Value

For the Drug Manufacturers - General subindustry, Astellas Pharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Price-to-Median-PS-Value falls into.



Astellas Pharma Median PS Value Calculation

Astellas Pharma's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=6.025*2.3917
=14.41

10-Year Median PS Ratio is 2.3917.
Astellas Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.025.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Astellas Pharma  (OTCPK:ALPMY) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Astellas Pharma's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=9.55/14.41
=0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Astellas Pharma Median PS Value Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma (Astellas Pharma) Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.